BTIG Research Reaffirms “Buy” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research report issued on Friday, Marketbeat.com reports. They currently have a $73.00 price target on the stock. BTIG Research’s target price indicates a potential upside of 82.50% from the company’s previous close.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. UBS Group assumed coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a report on Thursday, November 13th. They issued a “buy” rating and a $45.00 price objective on the stock. Wedbush reiterated an “outperform” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday. Finally, Guggenheim reissued a “buy” rating and set a $60.00 target price on shares of Oruka Therapeutics in a report on Friday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $56.67.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $40.00 on Friday. The firm has a fifty day moving average of $32.92 and a 200 day moving average of $27.59. The firm has a market cap of $1.94 billion, a PE ratio of -21.51 and a beta of -0.38. Oruka Therapeutics has a one year low of $5.49 and a one year high of $41.19.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, equities analysts predict that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Activity at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $32.37, for a total value of $226,590.00. Following the completion of the sale, the insider directly owned 34,018 shares in the company, valued at $1,101,162.66. This represents a 17.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 21,000 shares of company stock valued at $663,530 in the last ninety days. 24.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. purchased a new position in Oruka Therapeutics in the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets lifted its stake in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics News Summary

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Multiple brokerages raised or reaffirmed bullish ratings and lifted price targets (signals of stronger buy-side conviction and potential re-rating of the stock). Benzinga
• Positive Sentiment: Barclays raised its price target to $50 and set an “overweight” rating, implying meaningful upside from current levels. Benzinga
• Positive Sentiment: BTIG reiterated a “buy” and kept a $73 price target, the highest among recent notes, which can attract momentum investors. Benzinga Street Insider
• Positive Sentiment: Stifel Nicolaus raised its target to $72 and maintained a “buy,” reinforcing analyst consensus around significant upside. Benzinga
• Positive Sentiment: Guggenheim reaffirmed a “buy” with a $60 target and Wedbush kept an “outperform” at $45 — additional corroboration from the sell-side. Benzinga
• Positive Sentiment: Oruka reported Q4 results with EPS of ($0.45), beating consensus (($0.61)), which reduces short‑term execution risk and supports the bullish analyst activity. Press Release
• Positive Sentiment: Corporate update: ORKA-001 (EVERLAST-A) 16‑week data now expected in 2Q 2026 after rapid enrollment, with longer-term follow-up in 2H 2026 — an accelerated clinical timetable is a near-term catalyst for valuation. GlobeNewswire

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.